Herticad®

Trastuzumab injection 440 mg

Trastuzumab biosimilar is a recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells

Indication: It is used in MBC or EBC patients who have tumours with either overexpression of HER2 or HER2 gene amplification in:

  • Metastatic Breast Cancer (MBC)
  • Early Breast Cancer (EBC)
  • Metastatic Gastric Cancer (MGC)

Dosage and Administration : For intravenous (IV) infusion only. Do not administer as an IV push or bolus

Composition : Each vial contains lyophilised powder to be reconstituted

  • The first trastuzumab biosimilar approved by the Ministry of Health of the Russian Federation
  • Biosimilar Quality : Similarity proven based on assured quality, safety, & efficacy evidence
  • Manufactured in world class PIC/s approved plant in Russia
  • 225 patients Global trial data presented in ESMO 2016 Congress showed that Herticad and the innovator had equivalent Efficacy, Safety & Immunogenicity

For more information regarding Herticad®, please contact your local sales representative or email us at info@sayretherapeutics.com